

Assessment of the effectiveness and safety of Bibrocathol 2% eye ointment (Bibrocathol-POS 2%) in the treatment of chronic blepharoconjunctivitis

Submission date 03/02/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 08/03/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 09/09/2022	Condition category Eye Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aim

Blepharoconjunctivitis occurs when normal bacteria that live on the eyelid skin cause irritation and inflammation to the eyelids that spreads to the conjunctiva (the clear tissue covering the white part of the eye and the inside of the eyelids).

Bibrocathol is a well known antiseptic drug for the treatment of the signs and symptoms of chronic blepharoconjunctivitis, and is widely used in clinical practice. The aim of this study is to test the effectiveness and safety of Bibrocathol 2% eye ointment (Bibrocathol-POS 2%) in chronic blepharoconjunctivitis.

Who can participate?

Patients with chronic blepharoconjunctivitis may participate in this study if they do not yet require antibiotic treatment

What does the study involve?

The study includes four visits (screening, baseline, control assessment and final examination). The total duration of study for one patient is about 2-3 weeks. Eye examinations include measurement of visual acuity, intraocular pressure (the fluid pressure inside the eye), and slit-lamp biomicroscopy. A questionnaire is completed and physical examinations including blood pressure and weight measurement are performed at screening day. If applicable, a pregnancy test is carried out at screening. A patient diary is used to document the application of the investigational product by the patient.

What are the possible benefits and risks of participating?

The patient can benefit from bibrocathol and vehicle treatment or at least from the care and diagnostic supervision of the investigator. Eventually, it may be that there is no direct benefit from the participation in the study. However, participation in this study may possibly contribute to improved future treatment of other patients with the same or a comparable disease.

Where is the study run from?
URSAPHARM Arzneimittel GmbH (Germany)

When is the study starting and how long is it expected to run for?
November 2014 to October 2019

Who is funding the study?
URSAPHARM Arzneimittel GmbH (Germany)

Who is the main contact?
Dorothea Gross
d.gross@ursapharm.de

Contact information

Type(s)
Scientific

Contact name
Mrs Dorothea Groß

Contact details
Industriestrasse 35
Saarbrücken
Germany
66129
+49 (0)6805 9292 132
dorothea.gross@ursapharm.de

Additional identifiers

Clinical Trials Information System (CTIS)
Nil known

ClinicalTrials.gov (NCT)
Nil known

Protocol serial number
Nil known

Study information

Scientific Title
A multi-centre, randomized, double-masked, placebo-controlled, parallel-group, phase III study to assess efficacy and safety of Bibrocathol 2% eye ointment (Bibrocathol-POS 2%) in the treatment of chronic blepharoconjunctivitis

Study objectives
Assessment of a reduction in the signs and symptoms of chronic blepharoconjunctivitis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Approved 17/04/2017, Ethics Committee of Federal State Budgetary Educational Institution of Higher Education "Russian National Research Medical University n.a N.I. Pirogov" of the Ministry of Health of the Russian Federation (Ostrovityanova str. 1,117997, Moscow, Russian Federation; +7 (0)495 343 30 83; ek@rsmu.ru), ref: not available
2. Approved 10/04/2017, Ethics Committee of Federal State Budgetary Institution "Moscow Helmholtz Scientific Research Institute of Eye Diseases" of the Ministry of Healthcare of the Russian Federation (Sadovaya-Chernogryazskaya str. 14/19, 105062, Moscow, Russian Federation; +7 (0)495 623 41 61; info@igb.ru), ref: not available
3. Approved 17/05/2017, Ethics Committee of Federal State Budgetary Educational Institution of Higher Education "Saint Petersburg State Pediatric Medical University" of the Ministry of Healthcare of the Russian Federation (Litovskaya str. 2, 194100, Saint Petersburg, Russian Federation; +7 (0)812 295 9146; dogovor@gpma.ru), ref: not available
4. Approved 11/09/2017, Ethics Committee of Federal State Budgetary Educational Institution of Higher Education "Pavlov First Saint Petersburg State Medical University" of the Ministry of Healthcare of the Russian Federation (L'va Tolstogo str. 6/8, 197022, Saint Petersburg, Russian Federation; +7 (0)812 338 66-17; spbgmutrials@yandex.ru), ref: not available
5. Approved 26/05/2017, Local Ethics Committee of Regional Budgetary Healthcare Institution "Ivanovo Regional Clinical Hospital" (Luybimova str. 1, 153040, Ivanovo, Russia Federation; +7 (0) 4932 56 22 48; email: not available), ref: not available

Study design

Interventional multi-centre randomized double-masked placebo-controlled parallel-group trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Chronic blepharoconjunctivitis

Interventions

Patients are randomized with a 1:1 (verum: placebo) allocation ratio. A strip of the investigational product (about 5 mm) is administered in the conjunctival sac and on the lower and upper eyelid in the morning, at noon, and in the evening for 2 weeks.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Bibrocathol 2% eye ointment (Bibrocathol-POS 2%); 4,5,6,7-Tetrabromo-1,3,2-benzodioxabismol-2-ol

Primary outcome(s)

Signs of chronic blepharoconjunctivitis, expressed as a sum score which comprises the severity of:

1. Lid oedema measured using slit-lamp examination at screening, day 1, day 7 and day 15
2. Lid erythema measured using slit-lamp examination at screening, day 1, day 7 and day 15
3. Debris measured using slit-lamp examination at screening, day 1, day 7 and day 15
4. Hyperemia measured using slit-lamp examination at screening, day 1, day 7 and day 15
5. Pouting of Meibomian glands assessed by the investigator at screening, day 1, day 7 and day 15

Key secondary outcome(s)

The individual parameters:

1. Lid oedema measured using slit-lamp examination at screening, day 1, day 7 and day 15
2. Lid erythema measured using slit-lamp examination at screening, day 1, day 7 and day 15
3. Debris measured using slit-lamp examination at screening, day 1, day 7 and day 15
4. Hyperemia measured using slit-lamp examination at screening, day 1, day 7 and day 15
5. Pouting of Meibomian glands measured by investigator assessment at screening, day 1, day 7 and day 15

Completion date

28/10/2019

Eligibility

Key inclusion criteria

1. Written informed consent
2. Ambulatory male and female patients ≥ 18 years of age
3. Diagnosis of chronic blepharoconjunctivitis
4. A summarised score of signs and symptoms (sum score of severity of lid oedema, lid erythema, debris, hyperemia and pouting of Meibomian glands and additionally the patient's assessment of ocular discomfort) of ≥ 18 at baseline
5. Ability of the patient to cooperate (able to understand the provided information about the clinical trial, willing to comply with the requirements of the study protocol)
6. Consent to use adequate contraception
7. Women using adequate contraception with a negative pregnancy test (for women with childbearing potential), or women who had menopause 2 years before the start of the study or earlier

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

200

Key exclusion criteria

Non-inclusion criteria:

Ocular conditions:

1. Chronic blepharoconjunctivitis requiring antibiotic treatment
2. Therapy-resistant chronic blepharoconjunctivitis
3. Acute ocular and/or follicle or lid infection or active ocular inflammation other than blepharoconjunctivitis
4. Irritations of the outer eye that are related to corneal damage (e. g. erosions, injuries, burns)
5. Abnormal eyelid anatomy (other than due to chronic blepharoconjunctivitis)
6. Ocular surgery within 90 days (trauma, intraocular surgery, refractive surgery, palpebral surgery (e.g. ectopium OP), etc)
7. Severe dry eye syndrome also due to systemic diseases
8. Allergic eye disease
9. Glaucoma
10. IOP ≥ 21 mmHg (non-contact tonometry)
11. Patients with only one eye

Systemic condition:

12. Known hypersensitivity to the investigational product or any of the ingredients from the composition of the investigational product (or of placebo)
13. Severe systemic disease (incl. rheumatoid arthritis, ankylosing spondylitis)
14. Subjects with a history of malignancy of any organ system, treated or untreated, within the past 5 years, whether or not evidence of local recurrence or metastases exists

Concomitant medication:

15. Oral or topical antibiotics 2 weeks prior to and during the trial
16. Any other ocular antiseptics during the trial
17. Topical ocular or systemic corticosteroids 2 weeks prior to and during the trial (except chronic use of inhalative corticosteroids if on stable dose 1 month prior to and during the trial)
18. Topical ocular and systemic NSAIDs 2 weeks prior to and during the trial (low-dose oral acetylsalicylic acid and occasional use of painkillers is allowed)
19. Local ocular use of antihistamines 1 month and prior to and during the trial
20. Ocular α -sympathomimetics 1 month and prior to and during the trial

Other:

21. Patients who anticipate changes in their ongoing regimen of concurrent systemic therapies that could affect trial parameters
22. Pregnant or breastfeeding women
23. Women with childbearing potential, not using a reliable and medically accepted method of contraception (no pregnancy test is required in women, being 2 years after menopause)
24. Any systemic or ocular medical or physical condition which, in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the trial per protocol

25. Patients participating in another clinical trial at the same time
26. Patients taking any investigational product during the last 28 days
27. Patients already once included in this trial

Exclusion criteria:

1. Recall of the informed consent by the patient
2. Necessity to discontinue study treatment /placebo due to the occurrence of adverse events and/or exacerbation of concurrent diseases which prevent further participation in the study
3. Applicability of adjunctive therapy which is not permitted within this Protocol
4. Other conditions or events which require, in the physician's opinion, withdrawal of the patient from the study. If such a decision is taken based on adverse events related to intake of test medications or comparative medications, the Study Sponsor or its representatives shall be informed immediately
5. Non-performance of the case monitoring of the parameters specified in the Study Protocol
6. Intake/use by the patient of medications prohibited within this study
7. The patient's nonobservance of the procedures prescribed by the Protocol
8. Administrative reasons (discontinuation of the study by the Sponsor or regulatory authorities), and gross violations of the Protocol with a potential to impact the findings
9. Any changes in performing lid hygiene during the study
10. Wearing of contact lenses during the study

Date of first enrolment

15/01/2018

Date of final enrolment

15/02/2019

Locations

Countries of recruitment

Russian Federation

Study participating centre

Federal State Budgetary Educational Institution of Higher Education "Russian National Research Medical University n.a N.I. Pirogov" of the Ministry of Health of the Russian Federation

Moscow

Russian Federation

117997

Study participating centre

Federal State Budgetary Institution "Moscow Helmholtz Research Institute of Eye Diseases" of the Ministry of Healthcare of the Russian Federation

14/19, Sadovaya-Chernogryazskaya str.

Moscow

Russian Federation

105062

Study participating centre

Federal State Budgetary Educational Institution of Higher Education "Saint Petersburg State Pediatric Medical University" of the Ministry of Healthcare of the Russian Federation

2 Litovskaya str.

Saint Petersburg

Russian Federation

194100

Study participating centre

Federal State Budgetary Educational Institution of Higher Education "Pavlov First Saint Petersburg State Medical University" of the Ministry of Healthcare of the Russian Federation

6/8 L'va Tolstogo str.

Saint Petersburg

Russian Federation

197022

Study participating centre

Regional Budgetary Healthcare Institution "Ivanovo Regional Clinical Hospital"

1 Luybimova str.

Ivanovo

Russian Federation

153040

Sponsor information

Organisation

URSAPHARM Arzneimittel GmbH

Funder(s)

Funder type

Industry

Funder Name

URSAPHARM Arzneimittel GmbH

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication

IPD sharing plan summary

Other

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		17/05/2022	09/09/2022	Yes	No